Daclizumab high-yield process (HYP) is a humanized monoclonal antibody that binds to CD25 (alpha subunit of the interleukin-2 receptor) and modulates interleukin-2 signaling. Abnormalities in interleukin-2 signaling have been implicated in the pathogenesis of multiple sclerosis and other autoimmune disorders.
D aclizumab is a humanized monoclonal antibody that binds to the alpha subunit (CD25) of the high-affinity interleukin-2 receptor. 1, 2 Daclizumab treatment prevents signaling through the high-affinity interleukin-2 receptor and increases the availability of interleukin-2 to signal at its intermediate-affinity receptor. 1, 2 The use of daclizumab in patients with multiple sclerosis was based initially on the hypothesis that it directly antagonizes activated CD25+ effector T cells, which have long been implicated as key mediators of the pathogenic effects of multiple sclerosis. 1, 3 Notably, effector T-cell numbers and recall responses appear to be largely unaffected by daclizumab in vivo. 3 Other clinically important immunologic effects, including an increase in CD56 bright natural killer cells and a decrease in lymphoid-tissue inducer cells, have been observed. 4, 5 Daclizumab high-yield process (HYP) was developed for long-term subcutaneous administration and has less antibody-dependent cytotoxicity than earlier forms of daclizumab. 3 A randomized, placebo-controlled study showed that daclizumab HYP was efficacious as monotherapy over a period of 1 year in patients with relapsing-remitting multiple sclerosis. 6 Here, we report the results of the DECIDE study, which compared subcutaneous daclizumab HYP, administered at a dose of 150 mg every 4 weeks, with intramuscular interferon beta-1a (Avonex, Biogen), an approved therapy for relapsing multiple sclerosis, over a period of 2 to 3 years of treatment.
Me thods

Study Oversight
An advisory committee (see the Supplementary Appendix, available with the full text of this article at NEJM.org) participated in the study design. The advisory committee and an independent data and safety monitoring board provided study oversight in collaboration with the sponsors. Data were collected by the investigators, were analyzed by the sponsors, and remained confidential during the study. All the authors were involved in each stage of the manuscript development, made the decision to submit the manuscript for publication, and take responsibility for the accuracy and completeness of the data and analyses. The first draft of the manuscript was written by the first and last authors, with medical writing assistance paid for by the sponsors. The sponsors reviewed and provided feedback on the manuscript to the authors, who had full editorial control of the manuscript. The study was conducted and reported with fidelity to the study protocol, which is available at NEJM.org.
Patients
Key eligibility criteria included a confirmed diagnosis of relapsing-remitting multiple sclerosis (according to the 2005 McDonald criteria 7 ), an age of 18 to 55 years, cranial magnetic resonance imaging (MRI) showing lesions that were consistent with a diagnosis of multiple sclerosis, and a score of 0 to 5.0 on the Expanded Disability Status Scale (EDSS; scores range from 0 to 10.0, with higher scores indicating worse disability 8 ). Eligible patients had to have one of the following: two or more clinical relapses within the previous 3 years, with at least one clinical relapse occurring in the 12 months before randomization; or one or more clinical relapses and at least one new lesion on MRI that was not associated with the clinical relapse within the previous 2 years, with at least one of these events occurring in the 12 months before randomization. Key exclusion criteria are listed in the Supplementary Appendix.
All the patients provided written informed consent. Consent for continued participation was also obtained from patients who had a confirmed relapse or progression of disability. The study was approved by the relevant central and local ethics committees and was conducted in accordance with the International Conference on Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki.
Study Design and Treatment
Patients were randomly assigned, in a 1:1 ratio, to receive either subcutaneous daclizumab HYP at a dose of 150 mg every 4 weeks and intramuscular placebo once weekly or intramuscular interferon beta-1a at a dose of 30 μg once weekly and subcutaneous placebo every 4 weeks for at least 96 weeks and no more than 144 weeks (Fig. S1 in the Supplementary Appendix). Patients continued treatment up to week 144 or until the last enrolled patient completed week 96, which was the planned end of the study.
Patients were instructed to take prophylactic treatment for influenza-like symptoms during the first 24 weeks of therapy in order to reduce any potential for unblinding (since interferon beta therapy may be associated with influenzalike side effects). Randomization was conducted with the use of a centralized interactive voiceresponse system and stratified according to study site and prior use of interferon beta with the use of permuted-block randomization. All the patients and study personnel, including the treating neurologists, were unaware of the treatment assignments. All the efficacy assessments were performed by trained, certified, 9 examining neurologists or technicians who were not involved in other aspects of care of the patients in the study.
Study Procedures and End Points
Study visits occurred every 4 weeks and included in-clinic administration of daclizumab HYP (or matching placebo), dispensing of interferon beta-1a (or matching placebo) for at-home administration, and clinical and safety assessments. The EDSS score was determined at screening, at baseline, every 12 weeks thereafter, and during unscheduled visits for suspected relapse. Standardized MRI scans were obtained at baseline and at weeks 24, 96, and 144 and were evaluated in a blinded manner at a central MRI reading center (see the Supplementary Appendix). The 29-item Multiple Sclerosis Impact Scale, version 1 (MSIS-29; scores range from 1 to 100, with higher scores indicating greater physical or psychological effect of multiple sclerosis from the patient's perspective 10 ) , was administered at baseline and every 24 weeks thereafter. Unscheduled visits were performed to evaluate suspected relapses within 72 hours after symptom onset. The primary end point was the annualized relapse rate over a period of 144 weeks. Relapses were defined as new or recurrent neurologic symptoms that were not associated with fever or infection and that lasted at least 24 hours; the symptoms had to be accompanied by new objective neurologic findings on examination by the examining neurologist that were confirmed by the independent neurologic evaluation committee.
Secondary efficacy end points were the number of new or newly enlarged hyperintense lesions on T 2 -weighted MRI scans of the brain over a period of 96 weeks; the proportion of patients with confirmed progression of disability over a period of 144 weeks, which was defined as an increase of at least 1.0 point from a baseline score of at least 1.0 or an increase of at least 1.5 points from a baseline score of 0 on the EDSS that was confirmed at 12 weeks; the proportion of patients who did not have a relapse over a period of 144 weeks; and the proportion of patients with an increase from baseline (indicating increasingly negative effects of multiple sclerosis) of at least 7.5 points on the MSIS-29 physical subscale at 96 weeks. Additional end points are listed in the Supplementary Appendix.
Statistical Analysis
Efficacy analyses were based on the intention-totreat population (i.e., patients who underwent randomization and received ≥1 dose of study drug) unless otherwise specified. The number of new or newly enlarged hyperintense lesions on T 2 -weighted images at week 96 was assessed in all the patients with nonmissing postbaseline scan data. All the statistical tests were two-sided, with a significance level of 0.05.
The primary end point (the annualized relapse rate over a period of 144 weeks) was tested with the use of a negative binomial regression model, with adjustment for baseline relapse rate, history of interferon beta use (yes vs. no), baseline EDSS score (≤2.5 points vs. >2.5 points), and baseline age (≤35 years vs. >35 years). This analysis included relapses and time during the study up to the earliest of the following: the start of alternative medication for multiple sclerosis, 180 days after the receipt of the last dose, or the end of the treatment period.
Secondary end points were rank-ordered (in the order listed above) and were tested with the use of a sequential closed-testing procedure. If a comparison was not significant (at the 0.05 significance level), all lower-ranked end points were not considered to be statistically significant within the closed-testing procedure.
A negative binomial regression model, with adjustments for baseline volume of hyperintense lesions on T 2 -weighted images, history of interferon beta use, and age, was used to evaluate the number of new or newly enlarged hyperintense lesions on T 2 -weighted images at week 96, as compared with baseline. Analysis was based on observed data prior to switching to alternative multiple sclerosis medication. A Cox proportionalhazards model was used for the analysis of the proportion of patients who were relapse free and for the time to disability progression. Models were adjusted for history of interferon beta use, age, baseline EDSS value, and baseline relapse rate (relapse analysis only). For the analysis of progression, patients who had tentative disability progression at the visit at the end of the treatment period (or at the last EDSS assessment before initiation of alternative multiple sclerosis medication) without a confirmatory assessment were censored at the last EDSS assessment.
A logistic-regression model, with adjustments for baseline MSIS-29 physical subscale score, baseline Beck Depression Inventory II score, history of interferon beta use, and age, was used to evaluate the proportion of patients with clinically meaningful worsening on the MSIS-29 physical subscale. Missing data were imputed with the use of the mean of the nonmissing items (if <10 of 20 items were missing), or a randomeffects model was used to impute the missing MSIS-29 physical subscale score if the patient was missing 10 or more of the 20 items.
A detailed description of the statistical methods and sensitivity analyses is provided in the Supplementary Appendix. There were 20 tertiary end points described in the protocol and statistical analysis plan (see the complete list and results in Table S2 in the Supplementary Appendix); these analyses were not adjusted for multiple comparisons and are considered to be exploratory.
Safety analyses were summarized with the use of descriptive statistics for all the patients who received a dose of the study drug (safety population). Safety data that were collected up to 180 days after the last dose of daclizumab HYP were included. During the study, the protocol was amended to provide additional guidance on evaluating and managing cutaneous events and increased monitoring and management of liverfunction abnormalities (see the Supplementary Appendix).
R esult s Patients
A total of 1841 patients (919 patients in the daclizumab HYP group and 922 in the interferon beta-1a group) were enrolled at 244 study sites in 28 countries and underwent randomization between May 11, 2010, and April 16, 2012 . All the patients who underwent randomization received a dose of the study drug and were included in the intention-to-treat population. The characteristics at baseline were well balanced between the treatment groups (Table 1, and Table S1 in the Supplementary Appendix). The median duration of treatment was 108.7 weeks in the daclizumab HYP group and 111.4 weeks in the interferon beta-1a group. The overall rates of study withdrawal and treatment discontinuation were similar in the two treatment groups (Fig. S2 in the Supplementary Appendix).
Efficacy Results
Primary End Point
The adjusted annualized relapse rate was lower in the daclizumab HYP group than in the interferon beta-1a group (0.22 vs. 0.39, representing a 45% lower rate with daclizumab HYP; P<0.001) ( Table 2 ). The results of the prespecified and post hoc sensitivity analyses of the primary end point were consistent with those of the primary analysis (see the Supplementary Appendix).
Secondary End Points
The findings were also significant for the firstordered secondary end point. The number of new or newly enlarged hyperintense lesions on T 2 -weighted images at week 96 was 54% lower in the daclizumab HYP group than in the interferon beta-1a group (P<0.001) ( Table 2 ). The results of additional MRI-related outcomes, including the number of gadolinium-enhancing lesions, the number of new hypointense lesions on T 1weighted images, and the median annualized percentage of brain-volume loss, are shown in Table S2 in the Supplementary Appendix.
The results were not significant for the second-ordered secondary end point. At week 144, the estimated percentage of patients who had disability progression confirmed at 12 weeks as measured by the EDSS was 16% in the daclizumab HYP group and 20% in the interferon beta-1a group (P = 0.16) ( Fig. 1B and Table 2 ). Prespecified sensitivity analyses of confirmed disability progression showed that censoring the data after a tentative disability progression (i.e., after a patient had documented worsening in the EDSS score but before a confirmatory visit took place) was more common in the interferon beta-1a group than in the daclizumab HYP group, and the analysis of confirmed disability progression was sensitive to assumptions made about disability progression in these patients with censored data ( Table S3 in the Supplementary Appendix).
On the basis of the prespecified hierarchical testing plan, the results of the analyses of the third and fourth prespecified secondary end points were not considered to be significant. The estimated percentage of patients who were free from relapse at week 144 was 67% in the daclizumab HYP group and 51% in the interferon beta-1a group ( Fig. 1A and Table 2 ). Clinically meaningful worsening (defined as an increase of ≥7.5 points) in the patient-reported physical effect of multiple sclerosis, as assessed with the use of the MSIS-29 physical subscale, was observed in 19% of the patients in the daclizumab HYP group and 23% of those in the interferon beta-1a group ( Table 2) . Analyses of tertiary end points are shown in Table S2 and Fig. S3 in the Supplementary Appendix.
Safety
The overall incidence of adverse events was similar in the daclizumab HYP group and the interferon beta-1a group (91% in each group) ( Table 3 ). Adverse events, excluding relapse of multiple sclerosis, were reported in 90% of the patients in the daclizumab HYP group and in 89% of those in the interferon beta-1a group. The most common adverse events (in ≥10% of patients in either group), excluding relapse of multiple sclerosis, are listed in Table 3 . A total of 14% of the patients in the daclizumab HYP group and 9% of those in the interferon beta-1a group discontinued the study treatment owing to adverse events, excluding relapse of multiple sclerosis (Table 3, and Table S4 in the Supplementary Appendix).
Serious adverse events (excluding relapse of multiple sclerosis) were reported in 15% of the patients in the daclizumab HYP group and in 10% of those in the interferon beta-1a group ( Table 3) . The most common serious adverse events (in ≥3 patients in either group) are listed in Table S5 in the Supplementary Appendix. Five patients died during the study (Table 3) , including one in the daclizumab HYP group and four in the interferon beta-1a group; none of the deaths were considered by the investigators, while they were unaware of the treatment assignment, to be related to the study treatment.
Infections were reported in 65% of the patients in the daclizumab HYP group and in 57% of those in the interferon beta-1a group. Five patients (1%) in the daclizumab HYP group and three (<1%) in the interferon beta-1a group discontinued treatment owing to infection. Common infections (in ≥10% of the patients in either group) were nasopharyngitis (in 25% of the patients in the daclizumab HYP group and 21% of (44) * Plus-minus values are means ±SD. The characteristics at baseline were well balanced between the treatment groups (nominal P>0.05). The intention-totreat population included all the patients who underwent randomization and received at least one dose of study drug. Daclizumab high-yield process (HYP) was administered subcutaneously at a dose of 150 mg every 4 weeks, and interferon beta-1a was administered intramuscularly at a dose of 30 μg once weekly. † Race was determined by the investigator. ‡ Disease-modifying therapy included any prior disease-modifying or immunomodulatory therapy for multiple sclerosis, such as interferon beta-1a, interferon beta-1b, glatiramer acetate, natalizumab, mitoxantrone, azathioprine, fumaric acid, laquinimod, cyclophosphamide, mycophenolic acid, fingolimod, teriflunomide, methotrexate, alemtuzumab, cladribine, immune globulin, or temsirolimus. § Scores on the Expanded Disability Status Scale (EDSS) range from 0 to 10.0, with higher scores indicating worse disability. 8 ¶ Data on the 29-item Multiple Sclerosis Impact Scale (MSIS-29) were missing for eight patients in each treatment group. Scores range from 1 to 100, with higher scores indicating a greater physical or psychological effect of multiple sclerosis from the patient's perspective. 10 ‖ Data were missing for 14 patients in the interferon beta-1a group and for 19 in the daclizumab HYP group. ** Data were missing for 13 patients in the interferon beta-1a group and for 19 in the daclizumab HYP group. Table S6 in the Supplementary Appendix). Serious infections that were reported in more than one patient during the study were urinary tract infection, pneumonia, appendicitis, cellulitis, and viral infection. No cases of progressive multifocal leukoencephalopathy or infectious encephalitis were reported during the study.
Cutaneous events (e.g., rash, eczema, seborrheic dermatitis, acne, erythema, and pruritus) were reported in 37% of the patients in the daclizumab HYP group and in 19% of those in the 24 * The number of patients is the intention-to-treat population for each treatment group, excluding patients with missing data for baseline covariates unless otherwise noted. CI denotes confidence interval. † Secondary end points were rank-ordered (in the order listed here) and were tested with the use of a sequential closedtesting procedure. If a comparison did not indicate significance (at the 0.05 significance level), all lower-ranked end points were not considered to be statistically significant within the closed-testing procedure. Thus, the end points for the percentage of patients who were relapse free at week 144 and for clinical worsening on the basis of MSIS-29 physical subscale score were not tested because the P value for the secondary end point of disability progression confirmed at 12 weeks was 0.16. ‡ The analysis was performed in the subgroup of the intention-to-treat population who had a postbaseline scan, which included 841 patients in the interferon beta-1a group and 864 in the daclizumab HYP group. § The percentage of patients was estimated by means of the Kaplan-Meier product-limit method. ¶ Clinically meaningful worsening was defined as an increase of at least 7.5 points from baseline in the MSIS-29 physical subscale score. Data for 10 patients in the interferon beta-1a group and for 13 in the daclizumab HYP group were excluded owing to missing baseline covariates. 
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T h e ne w e ngl a nd jou r na l o f m e dicine interferon beta-1a group and led to treatment discontinuation in 5% of patients and 1% of patients, respectively. The most common cutaneous events were rash (in 7% of patients in the daclizumab HYP group and 3% of those in the interferon beta-la group) and eczema (4% and 1%, respectively). Serious cutaneous events were reported in 2% of the patients in the daclizumab HYP group and in less than 1% of those in the interferon beta-1a group ( Table S7 in the Supplementary Appendix). Serious cutaneous events that occurred in more than one patient were dermatitis and angioedema.
Hepatobiliary disorders were reported in 3% of the patients in the daclizumab HYP group and in 2% of those in the interferon beta-1a group, with serious hepatobiliary disorders occurring in 1% and less than 1%, respectively ( Table 3 ). Hepatic events occurred in 16% of the patients in the daclizumab HYP group and in 14% of those in the interferon beta-1a group, with serious hepatic events occurring in 1% and less than 1%, respectively ( Table 3 , and Table S8 in the Supplementary Appendix). Elevations in the alanine aminotransferase or aspartate aminotransferase level that were greater than 5 times the upper limit of the normal range occurred in 6% of the patients in the daclizumab HYP group and in 3% of those in the interferon beta-1a group ( Table 3) . Elevations of hepatic aminotransferase levels were observed more commonly during the first year of interferon beta-1a treatment than during the remainder of the study and were evenly distributed over time during daclizumab HYP treatment. Among patients who had elevations in the hepatic aminotransferase level of at least 3 times the upper limit of the normal range plus an elevation in the total bilirubin level greater than 2 times the upper limit of the normal range, one patient in each treatment group had a hepatic profile that was adjudicated by an independent committee as meeting the criteria of Hy's law 11 on the basis of a causality score of probable or higher 12 (Table 3) .
No between-group differences were observed in the incidences of potentially clinically significant hematologic laboratory abnormalities ( Table S9 in the Supplementary Appendix). During the study, malignant conditions were reported in seven patients in the daclizumab HYP group and in eight in the interferon beta-1a group ( Table 3 ).
Discussion
In this study involving a population of patients with active relapsing-remitting multiple sclerosis, 2 to 3 years of treatment with subcutaneous daclizumab HYP every 4 weeks was superior to the weekly administration of intramuscular interferon beta-1a with respect to relapse and lesion activity as assessed by means of MRI. Treatment with daclizumab HYP, as compared with interferon beta-1a, was not associated with a significantly lower risk of disability progression confirmed at 12 weeks.
Given the growing numbers of approved therapies, active-comparator studies are useful for evaluating new treatments for multiple sclerosis. When the treatment benefits of the active comparator are taken into account, the results of this study are consistent with the results of the 1-year, placebo-controlled SELECT study, 6 in which daclizumab HYP, as compared with placebo, was associated with a 54% lower relapse rate and a 57% lower risk of disability progression confirmed at 12 weeks.
Active-comparator studies are not without potential limitations. The risk of unblinding may be higher in these studies than in placebocontrolled studies, particularly when interferon beta is used as the comparator, given that it may be associated with influenza-like side effects. However, in this study, patients took prophylactic treatment for influenza-like symptoms, and the consistency of the clinical and MRI outcomes, as well as the similar treatment effect in Panel A shows the estimated proportion of patients who were relapse free at week 144 on the basis of Kaplan-Meier estimates. Relapses were defined as new or recurrent neurologic symptoms that were not associated with fever or infection and that lasted at least 24 hours. The analysis included relapses that were confirmed by an independent neurology evaluation committee. Data were censored at the earliest of the following: start of alternative multiple sclerosis medication, 180 days after the last dose for patients who discontinued treatment, or the end of the treatment period for patients who completed treatment. Panel B shows the estimated proportion of patients with disability progression confirmed at 12 weeks in each treatment group on the basis of Kaplan-Meier estimates. Confirmed disability progression was defined as an increase of at least 1.0 point on the Expanded Disability Status Scale (EDSS; scores range from 0 to 10.0, with higher scores indicating worse disability) from a baseline score of at least 1.0 or as an increase of at least 1.5 points from a baseline score of 0; the increase had to be confirmed 12 weeks later. Data were censored at the time of withdrawal from the study or at the time a patient switched to alternative multiple sclerosis medication if the patient withdrew from the study or switched to alternative medication without disability progression. Patients who had tentative disability progression at the visit at the end of the treatment period (or at the last EDSS assessment before the start date of alternative multiple sclerosis medication) and who had no confirmation assessment were censored at the date of the last EDSS assessment. The inset shows the same data on an enlarged y axis. CI denotes confidence interval. n engl j med 373;15 nejm.org October 8, 2015
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T h e ne w e ngl a nd jou r na l o f m e dicine patients with previous interferon exposure and those without previous exposure and in patients who had influenza-like symptoms and those who did not, suggest that unblinding was unlikely to have had a meaningful effect on the results.
In active-comparator studies, low event rates for end points such as confirmed disability pro-gression can reduce statistical power. The analysis of disability progression can also be complicated by informative censoring that may occur when patients leave the study after having had a worsening in their EDSS score but before completing their confirmatory visit. Long-term follow-up studies will continue to be important in assessing the treatment effects of multiple (11) Injection-site pain 102 (11) 96 (10) Urinary tract infection 98 (11) 96 (10) Influenza-like illness 346 (38) 88 (10) Adverse events of special interest Infection † 523 (57) 595 (65) Serious infection 15 (2) 40 (4) Cutaneous event † 176 (19) 344 (37) Serious cutaneous event 1 (<1) 14 (2) Hepatobiliary disorder † 16 (2) 26 (3) Serious hepatobiliary disorder 4 (<1) 7 (1) Hepatic event ‡ 130 (14) 144 (16) Serious hepatic event ‡ 4 (<1) 6 (1) sclerosis therapies on disability progression, because studies of even 2 to 3 years' duration capture only a small fraction of the lifelong treatment that most patients with multiple sclerosis will require. Interleukin-2 signaling plays a key role in both immunity against foreign antigens and maintenance of immune tolerance to self. 1 In this study, the risks of infection, cutaneous events, and elevations in hepatic aminotransferase levels were higher with daclizumab HYP than with interferon beta-1a. Why inflammatory events affecting organs such as the skin and liver also appeared to be facilitated by CD25 antagonism in some patients warrants further investigation. Although most of these events were self-limited, successful management of more serious cases will remain an important aspect of the overall risk-benefit profile of daclizumab HYP.
In conclusion, daclizumab HYP, a modulator of interleukin-2 signaling that was administered as a subcutaneous injection every 4 weeks, was associated with efficacy that was superior to that of weekly intramuscular injections of interferon beta-1a in the treatment of relapsing multiple sclerosis. The enhanced efficacy was accompanied by an increased frequency of adverse events, such that the net clinical benefit will need to be carefully considered by patients and their providers.
Supported by Biogen and AbbVie Biotherapeutics. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
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Event
Interferon Beta-1a (N = 922)
Daclizumab HYP (N = 919) number (percent)
Hepatic laboratory abnormality § Alanine aminotransferase or aspartate aminotransferase ≥3× ULN 80 (9) 96 (10) Alanine aminotransferase or aspartate aminotransferase >5× ULN 31 (3) 59 (6) Alanine aminotransferase or aspartate aminotransferase ≥3× ULN and total bilirubin >2× ULN 1 (<1) 7 (1) Met criteria of Hy's law 1 (<1) 1 (<1)
Malignant condition ¶ 8 (1) 7 (1) * None of the deaths were considered by the investigators, while they were unaware of the treatment assignment, to be related to treatment. The death in the daclizumab HYP group occurred 117 days after withdrawal from treatment and was due to secondary complications of aspiration pneumonia in a patient who had a multiple sclerosis relapse involving the brain stem. Deaths in the interferon beta-1a group were due to myocardial infarction, suicide, metastatic pancreatic cancer, and peritonitis. In addition, one death due to multiple sclerosis progression was reported in each treatment group after study withdrawal. Neither of the deaths was considered to be related to study treatment. † These events were assessed on the basis of the adverse events in the corresponding Medical Dictionary for Regulatory
Activities System Organ Class. ‡ Hepatic events were defined with the use of the standardized query in the Medical Dictionary for Regulatory Activities for drug-related hepatic disorders that uses the comprehensive search, which includes a broad range of preferred terms, including hepatic laboratory abnormalities and hepatobiliary events. § Patients with an alanine or aspartate aminotransferase level that was at least 3 times the upper limit of the normal range (ULN) and a total bilirubin level that was greater than 2 times the ULN were reviewed and assessed by an independent panel with the use of a structured approach. 12 One patient in each group had a hepatic profile that was considered to meet the criteria of Hy's law 11 on the basis of a causality score of probable or higher. No patient had a causality score of definitive. ¶ Eight malignant conditions were reported in the interferon beta-1a group during the study: endometrial cancer, malignant melanoma, metastatic pancreatic carcinoma, squamous-cell carcinoma, cervical squamous-cell carcinoma, oral squamous-cell carcinoma, testicular seminoma, and a malignant tongue neoplasm (stage unspecified) in one patient each. Seven malignant conditions were reported in the daclizumab HYP group during the study: basal-cell carcinoma, malignant brain neoplasm, invasive ductal breast carcinoma, squamous-cell carcinoma of the lip, thyroid cancer, transitional-cell carcinoma, and uterine cancer in one patient each. ........................................................................................... 
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ADDITIONAL METHODOLOGICAL DETAILS PROTOCOL AMENDMENTS
The protocol was amended three times. The first amendment, dated May 27, 2011, increased monitoring for liver-function tests to monthly and updated criteria for temporary suspension and discontinuation of study treatment for patients who developed elevated liver enzymes, provided a treatment algorithm for the evaluation and management of cutaneous events, and increased the sample size of the study from 1500 to 1800 patients based on recent clinical studies that suggested a lower relapse rate for the interferon beta-1a group. The second amendment, dated March 12, 2012, changed the criteria to prohibit concomitant treatment with medications with an established association with hepatoxicity or cutaneous hypersensitivity reactions and to make monthly liver-function testing results available to the treating neurologist before the administration of study treatment. The third amendment, dated April 29, 2013, modified the definition and rank ordering of some secondary and additional end points based on statistical powering assumptions and updated the statistical analysis section in the protocol.
KEY ELIGIBILITY CRITERIA
To be eligible for the study, women of childbearing potential were required to practice effective contraception during the study and be willing to continue contraception for 4 months after the last dose of study treatment. Exclusion criteria included a diagnosis of primary progressive, secondary progressive, or progressive relapsing multiple sclerosis; known intolerance, contraindication to, or history of noncompliance with intramuscular interferon beta-1a; history of malignancy, except for patients with a history of excised or treated basal cell carcinoma or fewer than three squamous cell carcinomas; history of severe allergic or anaphylactic reactions; known hypersensitivity to the study drugs or their excipients; history of abnormal laboratory results that in the opinion of the investigator are indicative of any significant or major disease that would preclude administration of either study drug; multiple sclerosis relapse that occurred within the 50 days before randomization and/or the patient has not stabilized from a previous relapse before randomization; any of the following abnormal blood tests at screening: hemoglobin ≤9.0 g/dl, platelets ≤100x10 9 /l, lymphocytes ≤1.0x10 9 /l, neutrophils ≤1.5x10 9 /l, alanine aminotransferase/serum glutamate pyruvate transaminase, aspartate aminotransferase/serum glutamic oxaloacetic transaminase, or gamma-glutamyl transferase equal to or greater than two times the upper limit of normal, or serum creatinine equal to or greater than the upper limit of normal; any previous treatment with daclizumab or other anti-CD25 monoclonal antibody; infection requiring hospitalization or intravenous antibiotics within 8 weeks before randomization; treatment with another investigational drug or approved therapy for investigational use within the 6 months before randomization; prior treatment with any of the following: total lymphoid irradiation, cladribine, T cell or T cell receptor vaccination, any therapeutic monoclonal antibody, except natalizumab; prior treatment with mitoxantrone, cyclophosphamide, fingolimod, or natalizumab within 1 year before randomization; prior treatment with any of the following medications or procedures within the 6 months before randomization: cyclosporine, azathioprine, methotrexate, mycophenolate mofetil, intravenous immunoglobulin, plasmapheresis, or cytapheresis; treatment with any of the following medications within the 30 days before randomization: intravenous corticosteroid treatment, oral corticosteroid treatment, or glatiramer acetate; and patients who were receiving an approved interferon beta preparation were not required to wash out from interferon beta before randomization, but interferon beta treatment must have been discontinued before randomization.
STUDY PROCEDURES AND END POINTS
Patients who prematurely discontinued study treatment before week 140 continued in the study but followed a modified visit schedule. Patients were required to discontinue from study treatment if they became pregnant, experienced a hypersensitivity reaction/allergic reaction to study treatment, required treatment with a disallowed concomitant medication, experienced a medical emergency that necessitated permanent discontinuation of study treatment, developed a chronic viral infection, developed liver-function test or laboratory abnormalities that were above set criteria, experienced severe depression or suicidal ideation, or at the request of the patient or at the discretion of the physician for medical reasons or noncompliance. Patients who prematurely withdrew from the study completed the early termination visit assessments and were requested to complete four follow-up visits. In the case of serious adverse events, patients were followed by the investigator until the event was resolved, stabilized, or returned to baseline. Patients were required to be withdrawn from the study if the patient desired to discontinue participation in the study, was unwilling or unable to comply with the protocol, or at the discretion of the investigator for medical reasons or noncompliance.
To prevent unblinding based on influenza-like symptoms following interferon beta-1a injection, patients were instructed to take nonsteroidal anti-inflammatory drugs (e.g., acetaminophen [paracetamol], ibuprofen, naproxen, aspirin) at the dose and frequency according to local labels before and for 24 hours after each injection of interferon beta-1a or matching placebo. To minimize unblinding that could potentially occur during routine clinical care, the study was designed so that there were separate study personnel who treated patients and who conducted efficacy assessments. Each patient had a primary and backup treating neurologist, examining neurologist, and examining technician. The treating neurologist was responsible for routine neurological care of the patient, assessment and treatment of adverse events and multiple sclerosis relapse, review of hematology and laboratory assessments, and monitoring and follow-up of abnormal hepatic tests. The examining neurologist was responsible for performing a detailed neurological exam and obtaining an Expanded Disability Status Scale (EDSS) score at each scheduled visit and at unscheduled visits, following referral by the treating neurologist. The examining technician (or examining neurologist) was responsible for administering the components of the Multiple Sclerosis Functional Composite (MSFC) at scheduled time points. The examining neurologist and examining technician were not involved with any other aspect of patient care and remained blinded to adverse events, concomitant medications, laboratory assessments, magnetic resonance imaging (MRI) data, and any other data that had the potential for revealing treatment assignment.
MRI Acquisition and Analysis
All scheduled MRI scans were evaluated at a central MRI reading center (NeuroRx Research, Montreal, Quebec, Canada). Investigational sites were required to send a test scan to NeuroRx for evaluation to ensure that the site's scanning techniques were appropriate before enrolling any patients in the study. Brain MRI scans with and without gadolinium were performed using standardized acquisition guidelines. Original data for MRI images were transferred from each site to the MRI reading center for blinded evaluation.
The following brain MRI scans were obtained: proton density-and T 2 -weighted twodimensional multislice turbo/fast spin-echo, T 1 -weighted three-dimensional spoiled gradient recalled echo (pre contrast), two-dimensional T 2 -weighted Fluid Attenuated Inversion Recovery (FLAIR), and three-dimensional spoiled gradient-recalled echo T 1 -weighted (post contrast). The following measurements were performed: T 2 -weighted lesion count and T 1 -weighted hypointense (nonenhancing) lesion count at baseline; new or enlarged T 2 -weighted lesion count and new T 1 -weighted nonenhancing lesion count at all postbaseline visits; and T 2 -weighted lesion volume, gadolinium-enhancing lesion count and volume, and total volume of nonenhancing T 1 -weighted lesions at all MRI visits. T 2 -weighted lesions were segmented using locally developed software and manually corrected as necessary. To be counted, lesions had to be three or more voxels in size. T 1 lesions were segmented within T 2 -weighted lesions using a threshold of 85% of the intensity of surrounding normal-appearing white matter (which corresponded approximately to the intensity of grey matter). Regions of acute T 1 hypointensity associated with gadolinium enhancement were removed. Baseline lesions had to be surrounded by normal-appearing tissue. New lesion counts were made relative to the prior visit and added over time intervals as appropriate to express results relative to baseline. For assessment of brain volume loss, normalized brain volume was determined at baseline, and percentage brain volume change was calculated automatically for each postbaseline MRI visit relative to baseline as assessed by Structural Image Evaluation using Normalization of Atrophy (SIENA) method. 1
STATISTICAL ANALYSES
A sample size of 900 patients per treatment group was estimated to provide approximately 90% power to detect a 24% reduction in the annualized relapse rate between the daclizumab highyield process (HYP) and interferon beta-1a treatment groups based on a negative binomial regression model with a 5% type 1 error rate. Power was estimated from simulations assuming a 21% drop-out rate, an average of 2.4 years of follow-up, and an annualized relapse rate of 0.27 in the interferon beta-1a group.
Annualized Relapse Rate
A negative binomial regression model adjusted for baseline relapse rate (number of relapses in the 3 years before study entry divided by three), history of prior interferon beta use, baseline EDSS score (≤2.5, >2.5), and baseline age (≤35, >35 years) was used to evaluate the differences between the daclizumab HYP group and the interferon beta-1a group in the annualized relapse rate. This analysis includes all independent neurology evaluation committee-confirmed relapses and follow-up time between the date of first dosing and either the end of treatment period visit or time of censoring. Data up to week 144 were included in the analysis. For the primary analysis of annualized relapse rate, censoring was at the earliest of start of alternative multiple sclerosis medication, 180 days after the last dose for patients who discontinued treatment, or the end of the treatment period for patients who completed treatment.
Sensitivity analyses were performed on the primary end point using the negative binomial regression model with the same covariates as used in the primary analyses.
Secondary End Points
A sequential closed testing procedure was used to evaluate the secondary end points, such that if statistical significance was not achieved from an end point for a comparison, all end points of a lower rank for that comparison were not considered statistically significant. The secondary end points were evaluated in the following order: number of new or newly enlarged hyperintense lesions on T 2 -weighted brain MRI over 96 weeks, disability progression as measured by the EDSS that was confirmed at 12 weeks, the proportion of patients who were relapse free, and the proportion of patients with an ≥7.5-point worsening from baseline on the 29-item Multiple Sclerosis Impact Scale (MSIS-29) physical subscale at 96 weeks. Relapse and EDSS progression outcomes were analyzed using data up to week 144; all other outcomes were assessed using data up to week 96.
Number of New or Newly Enlarged Hyperintense Lesions on T 2 -weighted MRI over a period of 96 Weeks
A negative binomial regression model adjusted for baseline volume of hyperintense lesions on T 2 -weighted MRI, history of prior interferon beta use, and baseline age (≤35, >35 years) was used to evaluate observed new or newly enlarged hyperintense lesions on T 2 -weighted MRI at the patient's last visit before or at week 96 compared with baseline. Data measured after a patient started alternative multiple sclerosis medication were excluded from the analysis and missing data were not imputed. To account for the timing of the MRI measurement, the logarithmic transformation of the scan number of the MRI assessment was included in the model as the offset parameter.
Disability Progression Confirmed at 12 Weeks
Estimated time to confirmed disability progression and the proportion of patients with confirmed disability progression at week 144 were based on the Kaplan-Meier product limit method. Disability progression confirmed at 12 weeks was defined as an ≥1.0-point increase on the EDSS from a baseline EDSS score ≥1.0 or an ≥1.5-point increase on the EDSS from a baseline EDSS score of 0 that was confirmed at 12 weeks. Between-treatment group differences were analyzed using a Cox proportional hazards model, adjusted by baseline EDSS values as a continuous variable, history of prior interferon beta use, and baseline age (≤35, >35 years). Patients were censored at the time of last EDSS assessment prior to withdrawal if they withdrew from the study. Patients with a tentative disability progression at the end of treatment period visit (or the last EDSS assessment before alternative multiple sclerosis medication start date) and no available confirmation assessment were censored at their last EDSS assessment. Prespecified sensitivity analyses included evaluating confirmed disability progression: 1) values for patients who met the criteria for a tentative disability progression but did not have a confirmatory assessment were imputed using the multiple imputation method described below for the analysis of disability progression confirmed at 24 weeks, and 2) assuming that all tentative progressions with no confirmatory assessments more than 74 days after the tentative progression were confirmed. Sensitivity analyses of disability progression confirmed at 12 weeks were performed using the same Cox proportional hazards model described above.
Proportion of Patients Free from Relapse
Time to first relapse was estimated based on the Kaplan-Meier product limit method. Data up to week 144 were included in the analysis. Between-treatment group differences were tested using a Cox proportional hazards model adjusted for baseline relapse rate, history of prior interferon beta use, baseline EDSS score (≤2.5, >2.5), and baseline age (≤35, >35 years). Only independent neurology evaluation committee-confirmed relapses were included in the analysis. Data after patients switched to alternative multiple sclerosis medication and data 180 days after the last dose for patients who discontinued treatment were excluded.
Proportion of Patients with Meaningful Worsening on the MSIS-29
A scoring algorithm was used to calculate the MSIS-29 physical and psychological subscale scores. 2 Patients with a ≥7.5-point worsening from baseline to week 96 on the MSIS-29 physical subscale were defined as having clinically meaningful worsening. 3 A logistic-regression model adjusted for baseline MSIS-29 physical subscale score, baseline Beck Depression Inventory-II score, history of prior interferon beta use, and baseline age (≤35, >35 years) was used to evaluate the proportion of patients with clinically meaningful worsening on the MSIS-29. For patients with missing data (<10 out of 20 items), the mean of the nonmissing items was used for the missing items. If the patient was missing 10 or more of the 20 items, or if the data was missing for any other reason, a random-effects model was used to impute the missing MSIS-29 physical subscale score. MSIS-29 physical subscale score data obtained after patients had taken alternative medication for multiple sclerosis during the study were set to missing and an imputed value was used instead.
Tertiary End Points
Annualized Relapse Rate by Time Period
The annualized relapse rate was evaluated at 6-month intervals (0 to 6 months, 6 to 12 months, 12 to 18 months, 18 to 24 months) and yearly intervals (1 year, 2 years) as a tertiary end point. The analyses included only relapses confirmed by the independent neurology evaluation committee and included the same covariates as the primary analysis on annualized relapse rate. For this analysis, a Poisson regression model adjusted for overdispersion using a Pearson scale parameter was used instead of a negative binomial regression model.
Annualized Relapse Rate for Severe or Serious Relapses
In the analysis of severe or serious relapses, all severe or serious relapses were included regardless of whether or not they were confirmed by the independent neurology evaluation committee or considered protocol defined. The statistical model and covariates were the same as the model specified for the analysis of the primary end point.
Disability Progression Confirmed at 24 Weeks
Disability progression confirmed at 24 weeks was defined as an ≥1.0-point increase on the EDSS from a baseline EDSS score ≥1.0 or an ≥1.5-point increase on the EDSS from a baseline EDSS score of 0 that was confirmed at 24 weeks. In the prespecified analysis of disability progression confirmed at 24 weeks, the presence or absence of confirmed disability progression was imputed using a multiple imputation approach in patients with a tentative disability progression and no available confirmatory assessment. Among patients with at least one tentative disability progression, the probability of confirmation for those with a missing EDSS assessment to confirm progression was estimated via logistic model adjusted for treatment group, baseline EDSS score (as a continuous variable), change in EDSS score from baseline to the time of the tentative disability progression, and the presence (or absence) of a relapse within the last 29 days of the tentative disability progression. For patients with multiple tentative disability progressions, the confirmed (if patient had a confirmed disability progression) or the last (if patient did not have any tentative disability progressions confirmed) tentative disability progression record was retained. The multiple imputation via this logistic-regression model was conducted 50 times. The Cox proportional hazards model as specified above was conducted on each of the 50 datasets. Finally, the hazard ratio, SE of this estimate, and P values were combined using Rubin's rule. 4 
Change in EDSS Score
Comparisons between treatment groups for the change from baseline in EDSS score by visit were estimated using Generalized Estimating Equations with an autoregressive covariance structure excluding assessments within 29 days of a relapse. The model was adjusted for baseline EDSS, history of prior interferon beta use, and baseline age (≤35, >35 years).
Improvement in Disability as Measured by EDSS Score
Sustained improvement in disability was defined as an ≥1.0-point decrease on the EDSS from a baseline EDSS score of ≥2.0 that was sustained for 12 weeks. Only patients with a baseline EDSS score of ≥2.0 were included in the analysis. Patients were censored at the time of withdrawal/switch if they withdrew from the study or switched to alternative multiple sclerosis medication without an improvement. Patients with a tentative improvement at the end of treatment period visit (or at the last EDSS assessment before alternative multiple sclerosis medication start date) and no confirmation assessment were censored at their last EDSS assessment. The time to confirmed improvement in disability was analyzed using a Cox proportional hazards model adjusted for baseline EDSS scores as continuous variable, history of prior interferon beta use, and baseline age (≤35, >35 years).
Multiple Sclerosis Functional Composite
The MSFC is composed of three objectively measured components: the average scores of two tests of the Timed 25-Foot Walk, the average of two trials for each hand (four total) of the 9-Hole Peg Test, and the number correct on the 3-Second Paced Auditory Serial Addition Test. 5 The MSFC score is calculated by creating z scores for each component based on a reference population and averaging them together. 5 Negative changes from baseline in MSFC score or component z scores indicate worsening in disability and positive changes indicate improvement in disability. 6 The changes in MSFC z scores at weeks 48 and 96 were analyzed and compared between treatment groups using an analysis of covariance model based on ranks with treatment group in the model adjusted for baseline MSFC z score, history of prior interferon beta use, and baseline age (≤35, >35 years). Data after the onset of alternative multiple sclerosis medication was set to missing and an imputed value was used. When data was missing for one of the required trials, data from the nonmissing trial was used in the calculation unless the reason the data was missing was due to physical limitations. If missing data was due to physical limitations for either one or all trials, then extreme values as suggested in the MSFC administration and scoring manual were used to impute the individual z scores. If the scores on all trials were missing for other reasons (e.g., missed visit, noncompliance) then the last observation carried forward (LOCF) method was used.
Visual Function Test at Weeks 48 and 96
Visual function was assessed using the low-contrast Sloan letter chart at 100%, 2.5%, and 1.25% contrast; scores were defined as the number of letters identified correctly (range, 0 to 60; higher scores indicate better visual function 7 ). In the prespecified analysis, treatment differences in the mean change from baseline at week 96 for 1.25% contrast was evaluated using an analysis of covariance model adjusted for baseline visual function test scores, history of prior interferon beta use, and baseline age (≤35, >35 years). For missing postbaseline scores, LOCF method was used to impute the missing score. Baseline values were not carried forward. If no value was available to be carried forward, the missing score was imputed using the treatment group mean in the same visit.
Cognitive Changes Measured by the Symbol Digit Modalities Test at Weeks 48 and 96
The Symbol Digit Modalities Test (SDMT) is the number of correct coded items completed in 90 seconds (range, 0 to 110; higher scores indicate faster cognitive processing speed 8 ). The prespecified approach was an analysis of covariance model on the change from baseline after imputing missing data using an last observation carried forward (LOCF) approach. Because the dropout rate in the interferon beta-1a group was higher earlier in the treatment period, the imputation method using LOCF was susceptible to bias; therefore, an analysis approach using a linear mixed model also was used. 9 In this model, a likelihood-based method is used to estimate the treatment effect and no explicit imputation on the missing data is performed. The analysis included observed data up to either the end of the study or use of alternative multiple sclerosis medication. Treatment was included as the fixed effect, time (visit) and intercept as the random effects, interaction terms of treatment and time, adjusted for baseline SDMT score, history of prior interferon beta use, and baseline age (≤35, >35 years).
MRI End Points
For all MRI end points, MRI data measured after a patient started alternative multiple sclerosis medication was excluded from the analysis and, if an imputation method was used, an imputed rather than an observed value was used in the analysis. MRI end points were evaluated at weeks 24 and 96.
The same analysis approach as was used to evaluate the secondary end point of number of new or newly enlarged hyperintense lesions on T 2 -weighted MRI over a period of 96 weeks was used to evaluate the number of new or newly enlarged hyperintense lesions on T2weighted MRI over a period of 24 weeks.
The number of new nonenhancing hypointense lesions on T 1 -weighted MRI over a period of 24 weeks or 96 weeks was evaluated using a negative binomial regression model adjusted for the baseline volume of hypointense lesions on T 1 -weighted MRI, history of prior interferon beta use, and baseline age (≤35, >35 years). The analysis included only patients with available baseline assessments. Missing data up to week 96 were imputed using the predicted value from a negative binomial regression model that included covariates for treatment group, baseline volume of hypointense lesions on T 1 -weighted MRI, history of prior interferon beta use, and baseline age (≤35, >35 years).
The total number of gadolinium-enhancing lesions at weeks 24 and 96 were analyzed using an ordinal logistic regression, adjusted for the number of gadolinium-enhancing lesions at baseline, history of prior interferon beta use, and baseline age (≤35, >35 years). The categories for number of lesions were zero, one, two, three to four, and five or more. The analysis included only patients with available baseline data. Missing postbaseline values were imputed using the LOCF method, or in the rare occasion when a patient skipped a visit, last observation carried backward. If no value was available to carry forward (or backward), values were imputed using the treatment group mean in the same visit.
The volume of new or newly enlarged lesions on T 2 -weighted MRI and median percentage change in the volume of hyperintense lesions on T 2 -weighted MRI at weeks 24 and 96 and new hypointense lesions on T 1 -weighted MRI over a period of 24 weeks or 96 weeks were compared between treatment groups using an analysis of covariance model based on ranks adjusted for the baseline volume of the corresponding lesion, history of prior interferon beta use, and baseline age (≤35, >35 years). The analysis included only patients with available baseline assessments. Missing MRI data values were imputed using the treatment group mean for that visit.
The annualized change in whole brain volume was calculated as percentage change divided by the number of days since the last scan multiplied by 365.25. The percentage changes were compared between treatment groups using analysis of covariance based on ranks adjusted for the baseline brain volume value, history of prior interferon beta use, and baseline age (≤35, >35 years). Missing postbaseline percent change values were imputed using the treatment group mean in the same visit, using the percent change values, respectively.
Change from Baseline in MSIS-29 Physical and Psychological Subscale Scores
Between-treatment group differences in MSIS-29 physical and psychological subscale scores (range, 0 to 100; higher scores indicate greater physical or psychological of multiple sclerosis from the patient's perspective 2 ) were evaluated based on an analysis of covariance model adjusted for baseline MSIS-29 physical or psychological subscale score as appropriate, baseline Beck Depression Inventory-II score, history of prior interferon beta use, and baseline age (≤35, >35 years). For the MSIS-29 physical subscale score, missing data were imputed as described above under secondary end points. For the MSIS-29 psychological subscale score, if a patient was missing data less than five of the nine items that make up the psychological subscale score, the mean of the nonmissing items was used for the missing items. If the patient is missing five or more of the nine items, or if the data was missing for any other reason, then a random-effects model was used to estimate the missing MSIS-29 psychological subscale score.
EuroQol 5-Dimensions Visual Analog Scale and Index
For the visual analog scale, patients rated their current health based on a 20-centimeter scale from 0 (worst imaginable health state) to 100 (best imaginable health state). For the summary index, patients rated their level of current health on five domains with three possible responses: no problems, some problem, or severe problems. A summary index (range, 0.0 to 1.0; higher scores indicate better patient-reported health status 10 ) was derived from the five domains using a scoring formula developed by the EuroQol Group. 10 For both end points, missing data was imputed using a mixed-effects regression model (random slope and intercept). Betweentreatment group differences were analyzed using an analysis of covariance model with a term for treatment group and adjusted for baseline visual analog scale score or summary index score as appropriate, baseline Beck Depression Inventory-II score, history of prior interferon beta use, and baseline age (≤35, >35 years).
Patients with No Evidence of Disease Activity over 96 Weeks
No evidence of disease activity was defined as patients without clinical (relapses and confirmed disability progression) and radiological (gadolinium-enhancing lesions and new or newly enlarged hyperintense lesions on T 2 -weighted MRI) disease activity. The proportion of patients who had no evidence of disease activity over 96 weeks was compared between treatment groups using a logistic-regression model adjusted for the baseline relapse rate, baseline EDSS score (≤2.5, >2.5), history of prior interferon beta use, and baseline age (≤35, >35 years).
Health Resource Utilization
The annualized rate of unscheduled visits at week 48 was the sum of the number of unscheduled visits recorded on weeks 24 and 48 divided by the total number of semiannual visits by week 48, multiplied by two. The annualized rate of unscheduled visits at week 96 was the sum of the number of unscheduled visits recorded up to week 96 divided by the total number of semiannual visits by Week 96, multiplied by two. Rates were calculated separately for multiple sclerosis-related and nonmultiple sclerosis-related visits for each treatment group.
SAFETY
Hepatic events were defined using the Standardized Medical Dictionary for Regulatory Activities Query drug-related hepatic disorderscomprehensive search, which includes a broad range of preferred terms, including hepatic laboratory abnormalities and hepatobiliary events.
RESULTS
RELAPSES
Preplanned and post hoc sensitivity analyses for annualized relapse rate supported the results of the primary analysis. In analyses using all protocol-defined relapses whether confirmed by the independent neurology evaluation committee or not, the annualized relapse rate was 43% lower with daclizumab HYP compared with interferon beta-1a (95% confidence interval [CI], 34 to 51%; nominal P<0.001). Eighty-nine percent of protocol-defined relapses in the daclizumab HYP group and 93% in the interferon beta-1a group were subsequently confirmed by the independent neurology evaluation committee. In a post hoc sensitivity analysis of all patientreported relapses, the annualized relapse rate was 42% lower (95% CI, 32 to 50%; nominal P<0.001) with daclizumab HYP compared with interferon beta-1a. Most patient-reported relapses in each treatment group (daclizumab HYP, 91%; interferon beta-1a, 93%) met the protocol definition for relapse and the number of patients who reported a relapse that was not considered a suspected relapse by the treating neurologist was similar in both groups (daclizumab HYP, n=21; interferon beta-1a, n=24).
Results also were similar to the primary analysis, when the relapse analysis was restricted to only those events that were considered serious or severe by the investigator. In the analysis of severe or serious relapses, the annualized relapse rate was 38% lower (95% CI, 16 to 54%; nominal P=0.002) with daclizumab HYP versus interferon beta-1a (Table S2) .
Influenza-like symptoms frequently occur following injection of interferon beta-1a and are a potentially unblinding symptom. An ad hoc analysis of the annualized relapse rate was performed based on the occurrence of the adverse event of influenza-like illness using the same analysis method as the primary analysis. Influenza-like illness was reported in 346 patients in the interferon beta-1a group and 88 patients in the daclizumab HYP group. Among the patients who did not experience influenza-like illness (daclizumab HYP, n=831; interferon beta-1a, n=576), the adjusted annualized relapse rates were 0.21 (95% CI, 0.18 to 0.24) and 0.36 (95% CI, 0.32 to 0.42), respectively. This represents a 43% lower annualized relapse rate in the daclizumab HYP group versus the interferon beta-1a group and is consistent with the result of the primary analysis (daclizumab HYP/interferon beta-1a rate ratio: 0.57 [95% CI, 0.48 to 0.69]). In the analysis of patients who reported one or more event of influenza-like illness, the annualized relapse rate was 37% lower in the daclizumab HYP group compared with the interferon beta-1a group (adjusted annualized relapse rate: daclizumab HYP, 0.27 [95% CI, 0.19 to 0.39]; interferon beta-1a, 0.43 [95% CI, 0.37 to 0.51]; rate ratio, 0.63 [95% CI, 0.43 to 0.93]).
Annualized relapse rates were higher in patients previously treated with interferon beta (daclizumab HYP, 0.31; interferon beta-1a, 0.48) than in interferon beta-naïve patients (daclizumab HYP, 0.16; interferon beta-1a, 0.32). However, the treatment effect for daclizumab HYP versus interferon beta-1a on the annualized relapse rate was similar in patients without prior interferon beta use (51% lower; P<0.001) compared with patients with prior interferon beta use (36% lower; P<0.001; P value for interaction=0.14). A post hoc analysis on annualized relapse rate was performed that excluded patients previously treated with interferon beta who were positive for interferon beta neutralizing antibodies at baseline. The adjusted annualized relapse rate was 0.39 (0.35 to 0.44) in the intramuscular interferon beta-1a group versus 0.22 (0.19 to 0.24) in the daclizumab HYP group (rate ratio, 0.55 [95% CI, 0.47 to 0.65]; P<0.001). The annualized relapse rate was 45% lower with daclizumab HYP compared with interferon beta-1a, which is similar to results from the primary analysis.
DISABILITY PROGRESSION
The Kaplan-Meier estimate of the percentage of patients with disability progression confirmed at 24 weeks was 9% versus 12% at week 96 and 13% versus 18% at week 144 in the daclizumab HYP versus interferon beta-1a groups, which represent a 27% lower risk of disability progression confirmed at 24 weeks (a tertiary end point) for daclizumab HYP compared with interferon beta-1a (P=0.03; Table S2 and Fig. S3 ). Because of an imbalance between the treatment groups in censoring of patients who left the study after experiencing a worsening in their EDSS score but who had not completed the confirmatory visit (interferon beta-1a, n=43 and n=67 versus daclizumab HYP, n=24 and n=41 for disability progression confirmed at 12 weeks and 24 weeks, respectively; Table S3 ), assumptions made about disability progression in censored patients impacted whether the test of statistical significance for disability progression was above or below the 0.05 threshold for both disability progression confirmed at 12 weeks and 24 weeks. Overall, the prespecified additional analyses of disability progression confirmed at 12 weeks and both the prespecified primary and additional analyses of the (tertiary) end point of disability progression confirmed at 24 weeks indicated a benefit of daclizumab HYP over interferon beta-1a except when it was assumed that disability progression did not occur in any patient who was censored after a tentative disability progression (Table S3 ).
SAFETY
Cutaneous Adverse Events
Forty-three (5%) patients in the daclizumab HYP group and 7 (1%) patients in the interferon beta-1a group discontinued study treatment due to a cutaneous adverse event. Fifteen (2%) patients in the daclizumab HYP group and 4 (<1%) patients in the interferon beta-1a group withdrew from the study treatment due to a cutaneous adverse event. There were no reported cases of Stevens-Johnson syndrome or toxic epidermal necrolysis. Figure S1 . Study Design.
SUPPLEMENTARY FIGURES
Patients received study treatment for a minimum of 96 weeks and up to a maximum of 144 weeks. The planned end of the study was when the last enrolled patient completed 96 weeks of treatment. EDSS denotes Expanded Disability Status Scale, HYP high-yield process, MRI magnetic resonance imaging, and RRMS relapsing-remitting multiple sclerosis.
Figure S2. Disposition of Patients in the DECIDE Study.
* All randomized patients received at least one dose of study drug. † One death occurred in the interferon beta-1a group during follow-up. ‡ One death occurred in the daclizumab HYP group after the patient withdrew from the study. HYP denotes high-yield process.
Figure S3. Time to Disability Progression Confirmed at 24 Weeks.
P value and risk reduction for disability progression confirmed at 24 weeks (≥1.0-point increase from a baseline Expanded Disability Status Scale (EDSS) score ≥1.0 or an ≥1.5-point increase from a baseline EDSS score of 0 confirmed at 24 weeks) with daclizumab high-yield process (HYP) compared with interferon beta-1a. As prespecified in the statistical analysis plan in patients with a tentative progression and no confirmatory assessment, the presence or absence of confirmed disability progression was imputed via multiple imputation using logistic regression (described in Additional Methodological Details). The data were analyzed using the Cox proportional hazards model on each dataset and hazard ratios, SE, and P values estimated from each imputed dataset were combined using Rubin's rule. 4 Tertiary end point, not corrected for multiple comparisons. BL denotes baseline, and CI confidence interval. ‡ Estimated proportion of patients based on the Kaplan-Meier product limit method. § Hazard ratio and P value were calculated using the same Cox proportional hazards models used in the analysis of disability progression confirmed at 12 weeks. In patients with a tentative progression and no confirmatory assessment, the presence or absence of confirmed disability progression was imputed via multiple imputation using logistic regression (see Additional Methodological Details). ¶ P value for comparison between treatment groups based on a Generalized Estimating Equations model adjusted for baseline EDSS score, history of prior interferon beta use, and baseline age (≤35, >35 years). ‖ Sustained improvement in disability was defined as an ≥1.0-point decrease on the EDSS from baseline EDSS score ≥2.0 that was sustained for 12 weeks. Only patients with a baseline EDSS score of ≥2 were included in the analysis. Hazard ratio and P value were calculated based on a Cox proportional hazards model, adjusted by baseline EDSS scores as continuous variable, history of prior interferon beta use, and baseline age (≤35, >35 years). Patients were censored at the time of withdrawal/switch if they withdrew from the study or switched to alternative multiple sclerosis medication without an improvement. Patients with a tentative improvement at the end of treatment period visit (or at the last EDSS assessment before alternative multiple sclerosis medication start date) and no confirmation assessment were censored at their last EDSS assessment. ** Negative changes from baseline in MSFC score or component z scores indicate worsening in disability and positive changes indicate improvement in disability. 6 † † Missing data up to week 96 were imputed. Data were imputed if data was missing or assessment was after the start date of alternative multiple sclerosis medication. ‡ ‡ P value for comparison between the daclizumab HYP and interferon beta-1a groups was based on an analysis of covariance model based on ranks and adjusted for baseline z score, history of prior interferon beta use, and baseline age (≤35, >35 years). § § Score range, 0 to 60; higher scores indicate better visual function. 7 ¶ ¶ Based on an analysis of covariance model with a term for treatment group, and adjusted for baseline visual function test scores, history of prior interferon beta use, and baseline age (≤35, >35 years). ‖‖ Range 0 to 110, higher scores indicate faster cognitive processing speed. 8 *** Analysis included observed data up to either the end of the study or use of alternative multiple sclerosis medication. Based on a random-effects model with all postbaseline data with treatment as the fixed effect, time and intercept as the random effects, interaction terms of treatment and time, and adjusted for baseline Symbol Digit Modalities Test score, prior interferon beta use, and baseline age (≤35, >35 years). † † † A subset of the intention-to-treat population with a baseline and nonmissing postbaseline scan. ‡ ‡ ‡ Adjusted mean, percent reduction, and P value estimated from a negative binomial regression model, adjusted for the baseline volume of hyperintense on T 2 -weighted MRI or hypointense lesions on T 1 -weighted MRI as appropriate, history of prior interferon beta use, and baseline age (≤35, >35 years). § § § P value for comparison based on ordinal logistic regression, adjusted for the number of gadolinium-enhancing lesions at baseline, history of prior interferon beta use, and baseline age (≤35, >35 years). ¶ ¶ ¶ P value based on analysis of covariance model based on ranks, adjusted for the baseline volume of hypointense lesions on T 1 -weighted MRI or volume of hyperintense lesions on T 2weighted MRI as appropriate, history of prior interferon beta use, and baseline age (≤35, >35 years). ‖‖‖ P value based on an analysis of covariance model based on ranks, adjusted for normalized brain volume, history of prior interferon beta use, and baseline age (≤35, >35 years). **** Range, 1 to 100; higher scores indicate greater physical or psychological effect of multiple sclerosis from the patient's perspective. 2 † † † † Based on an analysis of covariance model adjusted for baseline MSIS-29 physical or psychological subscale score as appropriate, baseline Beck Depression Inventory-II score, history of prior interferon beta use, and baseline age (≤35, >35 years). ‡ ‡ ‡ ‡ Range, 0 to 100; higher scores indicate better patient-reported health status. 10 § § § § Based on an analysis of covariance model with a term for treatment group and adjusted for baseline visual analog scale score or summary index score as appropriate, baseline Beck Depression Inventory-II score, history of prior interferon beta use, and baseline age (≤35, >35 years). ¶ ¶ ¶ ¶ Range, 0 to 1.0 higher scores indicate better patient-reported health status. 10 ‖‖‖‖ No evidence of disease activity was defined as patients without clinical (relapses and confirmed disability progression) and radiological (gadolinium-enhancing lesions and new or newly enlarged hyperintense lesions on T 2 -weighted MRI) disease activity. ***** Based on logistic-regression model adjusted for the baseline relapse rate, baseline EDSS score (≤2.5, >2.5), history of prior interferon beta use, and baseline age (≤35, >35 years). † † † † † Annualized rate was the sum of the number of unscheduled visits recorded divided by the total number of semiannual visits by the specified visit, multiplied by two. 0.73 (0.55 to 0.98) P value vs. interferon beta-1a 0.12 0.003 0.033 ¶ * Patients with a tentative progression and no confirmation assessment were censored at their last Expanded Disability Status Scale (EDSS) assessment and assumed not confirmed. CI denotes confidence interval. † Patients with a tentative progression and no confirmation assessment were assumed confirmed. ‡ Patients with a tentative disability progression and no confirmation assessment were assumed as either confirmed or not confirmed based on multiple imputation method adjusted for treatment group, baseline EDSS score (as a continuous variable), change in EDSS score from baseline to the time of the tentative disability progression, and relapse within the last 29 days of the tentative disability progression. § An ≥1.0-point increase from a baseline EDSS score ≥1.0 or an ≥1.5-point increase from a baseline EDSS score of 0 confirmed at 12 weeks (secondary end point, part of the hierarchical analysis). Based on a Cox proportional hazards model, adjusted by baseline EDSS scores as a continuous variable, history of prior interferon beta use, and baseline age (≤35, >35 years).
SUPPLEMENTARY TABLES
¶ Primary method prespecified in the statistical analysis plan. ‖ Sensitivity analysis prespecified in the statistical analysis plan. ** An ≥1.0-point increase from a baseline EDSS score ≥1.0 or an ≥1.5-point increase from a baseline EDSS score of 0 confirmed at 24 weeks (tertiary end point, P value not adjusted for multiple comparisons). Based on a Cox proportional hazards model, adjusted by baseline EDSS scores as a continuous variable, history of prior interferon beta use, and baseline age (≤35, >35 years). 
